Evidence map›Paper›PMID 26502977›Full record

ArticleMolecular neurodegeneration2015

Analysis of in vivo turnover of tau in a mouse model of tauopathy.

Kaoru Yamada, Tirth K Patel, Katja Hochgräfe, Thomas E Mahan, Hong Jiang, Floy R Stewart, Eva-Maria Mandelkow, David M Holtzman

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 71 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Ms4a4a deficiency ameliorates plaque pathology in a mouse model of amyloid accumulation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Multifaceted Roles of Aquaporins in the Pathogenesis of Alzheimer's Disease.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Tau kinetics in Alzheimer's disease.Frontiers in aging neuroscience · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Kaoru YamadaDepartment of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan. yamadaka@m.u-tokyo.ac.jp.
Tirth K PatelDepartment of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, 63110, USA. patelt@neuro.wustl.edu.
Katja HochgräfeMPI for Neurological Research, Hamburg Outstation, c/o DESY, Notkestr. 85, 22607, Hamburg, Germany. hochgraefe@mpasmb.desy.de.
Thomas E MahanDepartment of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, 63110, USA. mahant@wustl.edu.
Hong JiangDepartment of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, 63110, USA. jianh@neuro.wustl.edu.
Floy R StewartDepartment of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, 63110, USA. stewartf@neuro.wustl.edu.
Eva-Maria MandelkowMPI for Neurological Research, Hamburg Outstation, c/o DESY, Notkestr. 85, 22607, Hamburg, Germany. mand@mpasmb.desy.de.
David M HoltzmanDepartment of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, 63110, USA. holtzman@neuro.wustl.edu.
Hope Center for Neurological Disorders · USCenter of Advanced European Studies and Research · DEMax Planck Unit for Structural Molecular Biology · DEThe University of Tokyo · JP

Funding

Viral Vectors CoreP01NS074969 · NINDS · WASHINGTON UNIVERSITY · PI SNIDER, BARBARA JOY · 2012 to 2021
$13.0M
NINDS NIH HHS P01 NS074969
6 · The paper itself

Abstract

backgroundIntracellular accumulation of tau as neurofibrillary tangles (NFTs) is the hallmark of Alzheimer's disease (AD) as well as in other tauopathies. Tau is present not only in the cytoplasm but also in the extracellular space such as cerebrospinal fluid (CSF) and brain interstitial fluid (ISF). Although clearance is one critical parameter leading to such intracellular/extracellular tau accumulation, in vivo turnover of tau has not been well characterized. The current study has attempted to precisely determine in vivo turnover rates of tau utilizing tet-off regulatable mice. In particular, we assessed intracellular tau and extracellular tau, soluble tau, insoluble tau and phosphorylated tau at certain sites utilizing a combination of in vivo microdialysis, biochemical analysis and specific ELISAs recognizing each species. To examine the effect of a tauopathy-associated mutation on tau clearance, half-lives of various tau species were compared between the mice with a FTDP-17 mutation that induces β-sheet formation, ΔK280 mutation (pro-aggregant mice) and control mice with additional β-sheet breaking mutations (anti-aggregant mice).

resultsHere we report that tau is metabolized at much slower turnover rates in vivo than in cell culture. We found that insoluble tau in pro-aggregant mice had a significantly slower half-life (t1/2 = ~34.2 days) than soluble tau (t1/2 = ~9.7 days). In contrast, soluble tau phosphorylated in the proline rich region was cleared faster than total soluble tau. When comparing pro-aggregant mice to anti-agregant mice, turnover rates of soluble tau species were not significantly different.

conclusionsThe current study provides a comprehensive description of in vivo turnover of various tau species present in mice that express human tau. The turnover rate of soluble tau was not significantly altered between pro-aggregant mice and anti-aggregant mice. This suggests that altered conformation by ΔK280 does not have a major impact on clearance pathways for soluble tau. In contrast, different tau species displayed different half-lives. Turnover was significantly delayed for insoluble tau whereas it was accelerated for soluble tau phosphorylated in the proline rich region. These differences in susceptibilities to clearance suggest that aggregation and phosphorylation influences tau clearance which may be important in tau pathogenesis.

Indexed as

AnimalsBrainDisease Models, AnimalFrontotemporal DementiaMemoryMiceMice, TransgenicMutationTauopathiestau Proteinstau Proteins

Identifiers

PMID26502977
PMCPMC4621881
OpenAlexW1832926431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.